Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleura associated with previous asbestos exposure. Patients typically present late in the disease course. At present there is no curative treatment and the median survival is low. In this article, we explore whether MPM meets accepted criteria for initiation of a screening programme and we review potential screening strategies. These include blood-based biomarkers and radiological imaging. We conclude that, at present, there is insufficient evidence to support a screening programme for MPM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
